

04/05/2004

RECEIVED

GENENCOR LEGAL → 17038729306

NO. 649 0001

APR 06 2004

TECH CENTER 1600/2200

PATENT

Docket No. GC527- US
SN 09/060,872

- ☐ Urgent
- ☐ Confidential
- ☐ Action Required
- ☐ Reply Requested
- ☐ For Your Info

RECEIVED
CENTRAL FAX CENTER

APR 05 2004

OFFICIAL

FAX COVER SHEET

TO: Art Unit 1644

LOCATION: USPTO

Fax No.: (703) 872-9306 (Central Facsimile No.)

FROM: Aida Martinez for Kamrin T. MacKnight

LOCATION: GENENCOR INTERNATIONAL, INC.
Legal Department
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7549
Fax: 650-845-6504

DATE: April 5, 2004

NUMBER OF PAGES TO FOLLOW: 11 **SENT BY:** am

Re: Serial No. 09/060,872; Attorney Docket No. GC527- US

Attachments: Transmittal (1 page) in duplicate, and Amendment and Response to Office Action (9 pages).

The original of this facsimile will be sent to you via:

☐ Regular Mail ☐ Overnight Mail ☐ Hand Delivery ☒ Will Not Be Sent

☒ Please initial acknowledgment of receipt by return facsimile _____

NOTE: The information contained in this facsimile message is confidential and may be subject to attorney-client privilege and is intended only for the use of the above named individual(s). If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone(650/846-7517) and return the original transmission to us by mail.

GC527-US-faxcvl-pto

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Central Facsimile No. (703) 872-9306, Box AF, Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: April 5, 2004

By:

Aida Martinez

PATENT
Docket No. GC527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:

David A. Estell et al.

Serial No.: 09/060,872

Filed: April 15, 1998

For: Mutant Proteins Having Lower Allergenic
Response in Humans and Methods for
Constructing, Identifying and Producing Such
Proteins

Group Art. Unit: 1644

Examiner: Saunders, David A.

TRANSMITTAL LETTER

Box AF
Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Final Office Action dated February 9, 2004, enclosed please find the following document: Amendment and Response to Final Office Action.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC527). A duplicate of this paper is enclosed.

Respectfully submitted,

Date: April 5, 2004

Kamrin T. MacKnight
Kamrin T. MacKnight
Registration No. 38,230

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-5838
Fax: 650-845-6504

GC527 TRANS-RES 4-5-04

RECEIVED
CENTRAL FAX CENTER

APR 05 2004

I hereby certify that this correspondence is being sent by facsimile transmission in accordance with § 1.6(d) addressed to Art Unit 1644, Central Facsimile No. (703) 872-9306, Commissioner for Patents, Alexandria, VA 22313-1450 on the date shown below.

Date: April 5, 2004

By:

Aida Martinez

OFFICIAL

PATENT

Docket No. GC527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:

David A. Estell et al.

Group Art Unit: 1644

Serial No.: 09/060,872

Examiner: Saunders, David A.

Filed: April 15, 1998

For: Mutant Proteins Having Lower Allergenic
Response in Humans and Methods for
Constructing, Identifying and Producing Such
Proteins

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
MAILED FEBRUARY 9, 2004

Box AF
Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

In response to the Final Office Action mailed February 9, 2004, Applicants respectfully request reconsideration of the above-identified application in view of the following remarks. Applicants respectfully request reconsideration of the application in view of the following amendments and remarks. Amendments to the Claims are reflected in the listing of Claims which begins on page 2, while the Remarks begin on page 8. None of the amendments to the Claims is intended to narrow the scope of any of the amended Claims within the meaning of *Festo*¹.

¹ *Festo Corp. v. Shoketsu Kogyo Kabushiki Co.*, No. 95-1066, 2000 WL 1753646 (Fed. Cir. Nov. 29, 2000).